Core Viewpoint - VSING (08292) has entered into a memorandum of understanding with Regal Hotels International Holdings Limited (Regal Hotels) to create a new entertainment era, integrating VSING's interactive entertainment system into Regal Hotels' iconic venues, thereby transforming hotel lobbies into vibrant ecosystems for immediate communication and performance interaction [1] Group 1: Strategic Collaboration - The partnership aims to establish Hong Kong's first "hotel entertainment metaverse," where every stage, song, and digital interaction will form part of a social network within physical spaces [1] - This collaboration signifies VSING's first comprehensive entry into the hotel and tourism industry, expanding its business from nightlife venues to the global hotel industry chain [1] Group 2: Business Expansion and Vision - The initiative represents a significant milestone for VSING in building the largest AI-driven entertainment ecosystem in Asia, showcasing the company's commitment to expanding its global entertainment footprint [1] - The partnership emphasizes the integration of physical spaces with the digital economy, transforming leisure activities into data-driven participatory experiences [1]

Core Viewpoint - VSING has entered into a memorandum of understanding with Regal Hotels International Holdings Limited, marking the beginning of a new era in entertainment by integrating interactive entertainment systems into the hotel environment [1] Group 1: Strategic Partnership - The collaboration aims to create a vibrant and emotional ecosystem in hotel lobbies, allowing guests to engage in real-time communication and interactive performances [1] - This partnership signifies VSING's first comprehensive entry into the hotel and tourism industry, expanding its business from nightlife venues to the global hotel industry chain [1] Group 2: Technological Integration - The integration of VSING's interactive entertainment system into Regal Hotels' iconic locations will create a seamless ecosystem that merges technology, performance, and lifestyle [1] - The initiative will inspire guests to connect, actively participate in activities, and find a sense of belonging [1] Group 3: Vision for the Future - VSING and Regal Hotels aim to establish Hong Kong's first "hotel entertainment metaverse," where every stage, song, and digital interaction contributes to a social network within physical spaces [1] - This collaboration reflects VSING's commitment to expanding its global entertainment footprint and merging physical spaces with the digital economy, transforming leisure activities into data-driven participatory experiences [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 會 就 本 公 佈 之 全 部 或 任 何 部 分 內 容 而 產 生 或 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 VSING Limited （於開曼群島註冊成立之有限公司） （股份代號：8292） 自願性公佈 業 務 最 新 情 況－VSING進軍全球酒店業 本公佈是由VSING Limited（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出， 以 向 股 東 及 有 意 投 資 者 提 供 有 關 本 集 團 業 務 的 最 新 發 展 情 況。 諒 解 備 忘 錄（「諒 解 備 忘 錄」） 本 公 司 董 事 會（「董事會」）欣 然 宣 佈，其 附 屬 公 司V Sing International Limited已與富 豪 酒 店 國 際 控 股 有 限 公 司（「富豪酒店」）（股 份 代 號：00078）訂 立 諒 解 備 忘 錄。富 豪 酒 店 為 香 港 上 ...

11月12日晚间，北大医药公告，公司董事长、总裁徐晰人因涉嫌刑事犯罪已被重庆市江北区人民检察院批准逮捕。此前公司于2025年10月25 日、10月30日披露了徐晰人因被刑事拘留暂时无法正常履职的情况。 公告显示，目前公司董事陈岳忠根据授权代为行使董事长职责，常务副总裁余孟川根据授权代为行使总裁及法定代表人职责。公司强调控制权 未发生变化，董事会运作正常，公司财务及生产经营管理情况正常。 北大医药股份有限公司 董 事 会 二〇二五年十一月十三日 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: Regal Hotels International Holdings Limited (富豪酒店國際控股有限公司) (於百慕達註冊成立之有限公司) 呈交日期: 2025年11月6日 截至月份: 2025年10月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00078 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.1 HKD | | 200,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 2,000,00 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本聯合公佈之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不對因本聯合公佈全部或任何部份內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 (股份代號: 78) RH International Finance Limited 更 改 在 香 港 之 總 辦 事 處 及 主 要 營 業 地 點 更 改 在 香 港 之 主 要 營 業 地 點 更 改 在 香 港 之 總 辦 事 處 及 主 要 營 業 地 點 Regal Hotels International Holdings Limited（「富豪」）之董事會宣佈，自二零二五年十一 月三日起，富豪在香港之總辦事處及主要營業地點將更改為： 香港銅鑼灣怡和街68號20樓 （於英屬維爾京群島註冊成立之有限公司） (股份代號: 5425) 富豪之電話及傳真號碼維持不變。 更 改 在 香 港 之 主 要 營 業 地 點 Regal Hotels International Holdings Limited RH International Finance Limited 林秀芬 吳季楷 承董 ...

Core Points - The chairman and president of Beijing University Pharmaceutical, Xu Xiren, has been criminally detained and is currently cooperating with investigations, temporarily unable to perform his duties [1][2] - The company has stated that its control has not changed, and the board of directors is operating normally, with financial and operational management remaining stable [2] - Xu Xiren remains the actual controller of the company, having authorized other executives to perform his duties during his absence [2] Company Background - Xu Xiren has been in control of Beijing University Pharmaceutical for only three months, having acquired control through a transaction involving the purchase of 100% of Southwest Synthetic Pharmaceutical Group [3] - The company has a long history, originally established in 1965, and has undergone several ownership changes, including being part of the Ping An Group and later transitioning to Xu Xiren's control in late 2024 [4] - The company reported a revenue of 957 million yuan for the first half of 2025, a decrease of 5.04% year-on-year, while net profit increased by 15.51% to 100 million yuan [4] Market Performance - As of October 29, the stock price of Beijing University Pharmaceutical closed at 6.17 yuan per share, with a total market capitalization of 3.677 billion yuan [5]

Core Points - The chairman and president of Beijing University Pharmaceutical, Xu Xiren, has been criminally detained and is temporarily unable to perform his duties [1] - The company has stated that its control has not changed and that its board of directors is operating normally [2] - Xu Xiren remains the actual controller of the company despite his detention [2] Company Control and Management - The company has made arrangements for its operations, with Xu Xiren authorizing other executives to perform his duties during his absence [2] - Xu Xiren acquired control of Beijing University Pharmaceutical through a transaction in December 2024, purchasing the controlling stake for 1 yuan while assuming significant debts [3] - Xu Xiren has held the positions of actual controller, chairman, and president of the company since his appointment in July 2025 [4] Financial Performance - In the first half of 2025, the company reported revenues of 957 million yuan, a year-on-year decrease of 5.04%, while net profit attributable to shareholders reached 100 million yuan, an increase of 15.51% [4] - The termination of a long-term service contract with Peking University International Hospital in April 2025 is expected to reduce the company's sales revenue and net profit in the second half of 2025 [4] Market Reaction - As of October 29, the company's stock price closed at 6.17 yuan per share, with a total market capitalization of 3.677 billion yuan [5]

Core Viewpoint - The chairman and president of Beijing University Pharmaceutical (北大医药), Xu Xiren, has been criminally detained, affecting his ability to perform his duties, while the company's control and operations remain stable [2][6]. Group 1: Management Changes - Xu Xiren has temporarily delegated his responsibilities to board member Chen Yuezhong and executive vice president Yu Mengchuan due to personal reasons [5]. - The delegation of authority is effective from the date of the written authorization and will remain in effect until Xu Xiren provides written notice to terminate it [5]. Group 2: Company Operations - As of the announcement date, the company has stated that its control has not changed, the board is functioning normally, and its financial and operational management is stable [2][6]. - The company is currently unaware of the progress or conclusions of the investigation into Xu Xiren's detention [6]. Group 3: Financial Impact - Following Xu Xiren's leadership, the company has faced challenges, including the termination of a long-term service contract with Beijing University International Hospital, which is expected to reduce sales revenue by approximately 600 million yuan and net profit by about 40 million yuan in 2025 [7]. - The company anticipates a revenue decrease of approximately 1.027 billion yuan starting in 2026, which is about 49.85% of the 2024 revenue [7].

Core Viewpoint - The chairman and president of Beijing University Pharmaceutical, Xu Xiren, has been criminally detained, affecting his ability to perform duties, while the company has appointed other executives to take over his responsibilities [1][4]. Group 1: Company Announcement - On October 25, the company announced that Xu Xiren temporarily could not perform his duties due to personal reasons and authorized Chen Yuezhong to act as chairman and Yu Mengchuan as president [4]. - The authorization is effective from the date of signing until Xu Xiren provides written notice to terminate it [4]. - The company has assured that its governance structure and internal control mechanisms are intact, and operations remain normal despite the leadership change [4]. Group 2: Company Background - Beijing University Pharmaceutical was established in 1965 and listed on the Shenzhen Stock Exchange in 1997 [5]. - The company became a member of the Ping An Group in 2022 and is controlled by Xu Xiren [5]. - The company focuses on drug research, production, and sales, with a portfolio of 166 drug approvals and 13 first-generic drug approvals [5]. Group 3: Financial Performance - In the first half of the year, the company reported total revenue of 957 million yuan, a decrease of 5.04% year-on-year, while net profit increased by 15.51% to 100 million yuan [6].